ICON Public Limited Company (ICLR)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2,797 | 5,481 | 7,741 | 8,120 | 8,282 | 8,251 | 8,253 | 8,135 |
| Operating profit | $m | 1,012 | 838 | ||||||
| Net profit | $m | 328 | 153 | 505 | 612 | 791 | 229 | 329 | 837 |
| EPS reported | $ | 2.90 | 4.26 | ||||||
| Operating cashflow per share | $ | 13.21 | 21.09 | ||||||
| Capex per share | $ | 2.22 | 3.58 | ||||||
| FCF per share | $ | 10.99 | 17.52 | ||||||
| Free cash flow | $m | 862 | 1,346 | ||||||
| Net debt | $m | 2,755 | 2,565 | ||||||
| Book value equity | $m | 9,193 | 9,378 | ||||||
| Book value per share | $ | 116.4 | 121.2 | ||||||
| Number of shares | m | 78.97 | 77.37 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 62.83 | 40.45 | ||||||
| P/B LTM | x | 1.55 | 1.52 | ||||||
| P/S LTM | x | 1.73 | 1.73 | ||||||
| P/FCF LTM | x | 16.58 | 10.62 | ||||||
| EV/EBITDA LTM | x | 20.88 | 13.81 | ||||||
| EV/Sales LTM | x | 2.08 | 1.82 | ||||||
| Earnings Yield LTM | % | +1.59% | +2.47% | ||||||
| FCF Yield | % | +6.03% | +9.42% | ||||||
| Quality | |||||||||
| ROE | % | +2.49% | +3.54% | ||||||
| ROIC | % | +6.74% | +4.80% | ||||||
| Operating margin | % | +12.27% | +10.15% | ||||||
| Gross margin | % | +26.37% | +21.85% | ||||||
| FCF/Sales | % | +10.45% | +16.31% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -69.57% | -55.30% | ||||||
| Sales Growth YoY | % | -0.37% | -0.35% | ||||||
| Net Income Growth YoY | % | -71.02% | -58.45% | ||||||
| FCF Growth | % | -22.94% | +20.34% | ||||||
| Operating Profit Growth | % | -7.77% | -23.70% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.24 | 0.39 | ||||||
| Net Debt/EBITDA | x | 3.53 | 2.06 | ||||||
| EBIT/Net interest | x | 5.38 | 4.48 | ||||||
| Net debt/market cap | % | +23.81% | +27.14% | ||||||
| Net debt/Equity | x | 0.30 | 0.27 | ||||||
| Gross debt/equity | x | 0.39 | 0.37 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
ICON Public Limited Company (ICLR)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free